Search
Metaxalone
go.drugbank.com/drugs/DB00660ApprovedInvestigationalMetaxalone is a moderate to strong muscle relaxant used in the symptomatic treatment of musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions.
Ibutilide
go.drugbank.com/drugs/DB00308ApprovedIbutilide is a Class III antiarrhythmic agent available in intravenous formulations.
Synonyms: N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamideTipifarnib
go.drugbank.com/drugs/DB04960InvestigationalIn June 2005, the FDA issued a Not Approvable Letter for Zarnestra. … Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer.
Dapoxetine
go.drugbank.com/drugs/DB04884InvestigationalIn a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to placebo. … Alza submitted a NDA to the FDA for dapoxetine for the treatment of premature ejaculation in December 2004.
Tolperisone
go.drugbank.com/drugs/DB06264InvestigationalBased on existing clinical data, Tolperisone is not sedating and does not interact with alcohol. … It possesses a high affinity for nervous system tissue, reaching highest concentrations in brain stem, spinal cord and peripheral nerves.
VX-148
go.drugbank.com/drugs/DB06103ExperimentalThe IMPDH enzyme plays a key role in regulating immune response and proliferation of specific cell types, including lymphocytes. VX-148 is a developed for the treatment of autoimmune diseases.
SYN-101
go.drugbank.com/drugs/DB05958ExperimentalSYN101 is comprised of an immune cell specific antibody linked to an ALK5 inhibitor payload to selectively block TGF-b signalling in immune cells. … SYN-101 is an investigational antibody-drug conjugate developed for the treatment of cancer.
Benzimate
go.drugbank.com/drugs/DB05170ExperimentalIt is currently under investigation by AmpliMed and is in phase I of clinical trial. … The anti-cancer and anti-viral activity of the benzimidazoles was originally investigated by the Proctor & Gamble Company beginning in the 1990's.
HGS-TR2J
go.drugbank.com/drugs/DB05895ExperimentalHGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies.